// App-Quantinova.ai

: Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non–muscle-invasive bladder cancer: A phase 1 study.

Researchers

Presenter

  • F. Johannes P. van Valenberg

Principal Investigators

  • Christopher Cutie

  • Sumeet Kaur Bhanvadia

  • Kirk A. Keegan

  • Shalaka Hampras

  • Hussein Sweiti

  • John Maffeo

  • Shu Jin

  • Albert Chau

  • Don Reynolds

  • Crysti Iarossi

  • April Kelley

  • Xiang Li

  • Katherine Stromberg

  • Michiel Sedelaar

  • Jessica Steenbruggen

  • Diederik Meindert Somford

  • Alfred Alfred Witjes

Medical Centers

  • Canisius Wilhelmina Hospital, Department of Urology, Nijmegen, Netherlands

  • Janssen Research & Development, Lexington, MA

  • Datacision Limited, London, United Kingdom

Locations

  • United Kingdom

  • Netherlands

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Prospective

Phase

  • I

Study Id's

  • NCT02720367

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved